Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Scientific Advisory Board Update

Tuesday, February 13, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VolitionRx's Scientific Advisory Board recently convened to provide guidance on various research projects. The board aims to ensure that the questions posed during research are clinically relevant. Chief Innovation Officer Terry Kelly shared insights in a video following the meeting, highlighting the importance of the board's role in the company's ongoing efforts.
Price reaction · baseline $21.8 (2024-02-13T15:55:00.000Z) · hit during market hours · 5 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-4.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • The Scientific Advisory Board is actively guiding ongoing projects.
  • The meeting emphasizes clinically relevant questions in research.
  • Engagement from leadership, such as Terry Kelly, showcases commitment.

Full Press Release Details

Following last year’s Scientific Advisory Board meeting , our Scientific Advisory Board met again to guide the various projects we are working on, while ensuring we are asking clinically relevant questions while we continue our research.
Hear from Volition Chief Innovation Officer, Terry Kelly, in her video below.

Related Articles

• Press Releases VolitionRx Announces Collaboration with Sysmex
• Press Releases VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Announces Collaboration with Sysmex

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was the purpose of the Scientific Advisory Board meeting?

The meeting aimed to guide ongoing projects and ensure clinically relevant questions are addressed.

Who is Terry Kelly?

Terry Kelly is the Chief Innovation Officer at VolitionRx.

What is the significance of the Nu.Q NETs Test?

The Nu.Q NETs Test is important for Ebola triage and treatment monitoring.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare VolitionRx Scientific Advisory Board Terry Kelly clinical research Ebola Triage
Last updated: Feb 13, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk